Tomuzotuximab

DB15178Investigational

Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed

Resolves to

Compound

UNII5P637IXG16CAS1646321-00-7

Targets

P00533EGFR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tomuzotuximab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account